Fibrosarcoma clinical trials

The registry lists 69 studies for Fibrosarcoma across more than 10 countries. 7 are recruiting or about to start. 4 of them are mainly about Fibrosarcoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-13. Counting its 2 narrower conditions too, such as Neurofibrosarcoma: 150 studies, 31 open.

Get an email when these change. Save the Fibrosarcoma studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 48
Status unknown: 7
Terminated: 5
Recruiting: 5
Active, not recruiting: 1
Not yet recruiting: 1

Phase

Phase 2: 39
Phase 3: 14
Phase 1: 12
Early Phase 1: 1

Where

United States: 39
United Kingdom: 16
France: 13
Canada: 12
Belgium: 11
Netherlands: 10

Who runs them

European Organisation for Research and Treatment of Cancer - EORTC (15) · National Cancer Institute (NCI) (8) · Children's Oncology Group (5) · Valerio Therapeutics (2) · Maria Sklodowska-Curie National Research Institute of Oncology (2) · Societe Internationale d'Oncologie Pediatrique (2) · Memorial Sloan Kettering Cancer Center (2) · OHSU Knight Cancer Institute (2)

What is being tested here

Drugs under test in Fibrosarcoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ifosfamide	1	7	11
Doxorubicin	1	6	10
Pazopanib	1	1	3
Ersodetug	1	1	1
Selinexor	1	0	1
Tislelizumab	1	0	1
Liposomal doxorubicin	1	0	1
Multiple TAA-loaded Dendritic Cell Vaccine	1	0	1
Imatinib	0	0	4
Paclitaxel	0	0	2

Drug classes tested here Alkylating agents 1 open · Tyrosine kinase inhibitors (TKIs) 1 open · Antimitotic agents 4 · HDAC inhibitors 3 · Angiogenesis inhibitors 3

Coming up

1phase 3 study under way

3studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 3, phase 3 first

Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism · Phase 3 · Rezolute
Apr 2027A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning · Ricoh USA, Inc.
Jul 2027Agnostic Therapy in Rare Solid Tumors · Instituto do Cancer do Estado de São Paulo

Who these studies take

Of the 5 Fibrosarcoma studies recruiting now, 2 (40%) set no upper age limit and 3 (60%) stop at 75 or younger. 2 (40%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 5
Age	Women	Men
10	1 (20%)	1 (20%)
18	5 (100%)	5 (100%)
30	5 (100%)	5 (100%)
40	4 (80%)	4 (80%)
50	4 (80%)	4 (80%)
65	4 (80%)	4 (80%)
75	3 (60%)	3 (60%)
85	2 (40%)	2 (40%)

Across all 69 studies, recruiting or not: 33% stop at 75 or younger and 25% at 65; 48% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 50 of 69. Browse all 69 → or search them.